簡介：
Vitae Pharmaceuticals is a clinical stage biotechnology company focused on discovering and developing novel, small molecule drugs for diseases that represent large market opportunities where there are significant unmet medical needs. We are developing a robust and growing portfolio of novel product candidates generated by Contour®, our proprietary structure-based drug discovery platform. Our team of accomplished scientists utilizes Contour to rapidly discover highly potent and selective product candidates for validated but difficult-to-drug targets in multiple disease areas. Our most advanced product candidates include VTP-34072, which commenced a Phase 2 clinical trial for the treatment of type 2 diabetes in July 2014, with data expected in the first half of 2015, and VTP-37948, which is in Phase 1 clinical trials for the treatment of Alzheimer's disease, or Alzheimer's, with data expected in the second half of 2014. Both product candidates are being exclusively developed and following regulatory approval, if any, commercialized by Boehringer Ingelheim GmbH, or BI, under separate collaborations. These collaborations have provided us with an aggregate of $152.4 million in funding as of June 30, 2014, including upfront license fees, research funding and success-based milestone payments as well as equity investments. In addition, we have several wholly-owned product candidates advancing in preclinical studies, including: VTP-43742 for the treatment of autoimmune disorders, where the immune system attacks normal tissues, with Phase 1 proof-of-concept data, which is the demonstration of therapeutic activity, expected by the end of 2015; VTP-38443 for the treatment of acute coronary syndrome, which includes unstable angina and heart attacks; and VTP-38543 for the treatment of atopic dermatitis, an immune system mediated inflammation of the skin. However, we currently do not hold any active authorizations to conduct clinical trials with respect to any of our wholly-owned product candidates and, at this time, we rely on BI for the conduct of clinical trials for our two partnered product candidates.